Oxygenta Pharmaceutical Ltd
Incorporated in 1990, Oxygenta Pharmaceutical Ltd manufactures Bulk Drugs and API including Pharmaceutical preparation, and Organic Fine Chemicals.
- Market Cap ₹ 133 Cr.
- Current Price ₹ 39.6
- High / Low ₹ 52.3 / 25.0
- Stock P/E
- Book Value ₹ -7.47
- Dividend Yield 0.00 %
- ROCE -46.6 %
- ROE %
- Face Value ₹ 10.0
Pros
- Company is expected to give good quarter
Cons
- Company has low interest coverage ratio.
- Promoter holding is low: 29.7%
- Debtor days have increased from 46.8 to 120 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
0 | 0 | 2 | 6 | 12 | 8 | 13 | 21 | 14 | 52 | 61 | 31 | 37 | |
0 | 1 | 6 | 10 | 16 | 13 | 17 | 23 | 22 | 48 | 59 | 38 | 48 | |
Operating Profit | -0 | -1 | -3 | -4 | -4 | -5 | -4 | -2 | -8 | 4 | 1 | -7 | -10 |
OPM % | -142% | -67% | -34% | -59% | -31% | -10% | -57% | 7% | 2% | -23% | -28% | ||
0 | -0 | 0 | 0 | 0 | 1 | 1 | 0 | 4 | 2 | 1 | -1 | -0 | |
Interest | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 2 |
Depreciation | 0 | 0 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 3 |
Profit before tax | -0 | -2 | -4 | -7 | -6 | -6 | -4 | -3 | -6 | 3 | -0 | -11 | -15 |
Tax % | 0% | 0% | -5% | 11% | 0% | -2% | -1% | 7% | 3% | 7% | -24% | -2% | |
-0 | -2 | -4 | -6 | -6 | -6 | -5 | -3 | -6 | 3 | -1 | -12 | -16 | |
EPS in Rs | -0.24 | -1.64 | -4.21 | -5.99 | -5.39 | -5.70 | -4.44 | -3.19 | -5.68 | 2.87 | -0.43 | -8.15 | -6.45 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | 19% |
3 Years: | 31% |
TTM: | 25% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | -4% |
TTM: | -81% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 35% |
3 Years: | % |
1 Year: | 26% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
Last Year: | % |
Balance Sheet
Figures in Rs. Crores
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 14 | 14 | 33 |
Reserves | -14 | -15 | -19 | -26 | -32 | -38 | -42 | -45 | -51 | -48 | -49 | -60 | -58 |
4 | 8 | 11 | 15 | 17 | 19 | 19 | 22 | 27 | 48 | 52 | 68 | 54 | |
13 | 14 | 17 | 19 | 24 | 27 | 30 | 34 | 33 | 24 | 14 | 32 | 35 | |
Total Liabilities | 14 | 17 | 18 | 18 | 20 | 19 | 17 | 21 | 19 | 34 | 31 | 54 | 64 |
12 | 12 | 16 | 12 | 13 | 12 | 12 | 12 | 11 | 16 | 20 | 28 | 30 | |
CWIP | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
1 | 2 | 2 | 6 | 7 | 6 | 5 | 9 | 7 | 17 | 11 | 26 | 34 | |
Total Assets | 14 | 17 | 18 | 18 | 20 | 19 | 17 | 21 | 19 | 34 | 31 | 54 | 64 |
Cash Flows
Figures in Rs. Crores
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
-0 | -1 | -3 | -4 | 1 | 1 | 1 | -8 | -3 | -2 | -2 | -2 | |
0 | -3 | -2 | 1 | -2 | -1 | -0 | -1 | -0 | -7 | -5 | -10 | |
0 | 4 | 4 | 3 | 1 | 0 | -1 | 8 | 3 | 9 | 6 | 11 | |
Net Cash Flow | 0 | 1 | -1 | 0 | -0 | 0 | -0 | 0 | 0 | 0 | -0 | -0 |
Ratios
Figures in Rs. Crores
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 128 | 38 | 44 | 39 | 14 | 9 | 11 | 11 | 10 | 120 | ||
Inventory Days | 33 | 84 | 41 | 122 | 57 | 121 | 100 | 121 | 56 | 182 | ||
Days Payable | 10,165 | 1,800 | 667 | 599 | 396 | 203 | 190 | 137 | 50 | 369 | ||
Cash Conversion Cycle | -10,004 | -1,678 | -582 | -439 | -325 | -73 | -79 | -5 | 16 | -68 | ||
Working Capital Days | -1,576 | -616 | -454 | -512 | -431 | -156 | -261 | 6 | 15 | 1 | ||
ROCE % | -23% | -70% | -188% | -1% | -47% |
Documents
Announcements
- Compliance Certificate Under Regulation 7(3) Of The SEBI (Listing Obligations And Disclosures Requirements) Regulations, 2015 For The Financial Year Ended 31St March, 2024. 2d
- Compliance Certificate Under Reg.40 (9) Of SEBI (LODR) Regulations, 2015 For The Financial Year Ended 31St March, 2024. 25 Apr
-
Draft Letter of Offer
25 Apr - Mark Corporate Advisors Pvt Ltd ("Manager to the Offer") has submitted to BSE a copy of Draft Letter of Offer to the Equity Shareholders of …
-
Detailed Public Statement
18 Apr - Mark Corporate Advisors Pvt Ltd ("Manager to the Offer") has submitted to BSE a copy of Detailed Public Statement under Regulations 13(4), 14(3) and 15(2) …
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
15 Apr - With reference to the above, we are enclosing the certificate dated 03.04.2024, issued by M/S Venture Capital and Corporate Investment Private Limited, RTA of the …
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
-
Financial Year 2006
from bse
Products:[1]
Losartan potassium intermediate, Gabapentin intermediate, Antihypertensive drugs, Anti
cancer drugs, Antiulcer drugs, Antiretroviral drugs, Antihypertensive drugs, Antiviral drugs.